Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin.
暂无分享,去创建一个
M. Detmar | K. Claffey | S. Ledbetter | A. Papadopoulos-Sergiou | C. Perruzzi | D. Senger | C. Peruzzi
[1] L. Brown,et al. Osteopontin at the Tumor/Host Interface , 1995, Annals of the New York Academy of Sciences.
[2] G. Rodan. Osteopontin Overview , 1995, Annals of the New York Academy of Sciences.
[3] D. Cheresh,et al. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. , 1995, Journal of cell science.
[4] H. Dvorak,et al. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. , 1995, The Journal of investigative dermatology.
[5] K. Alitalo,et al. Endothelial receptor tyrosine kinases involved in angiogenesis , 1995, The Journal of cell biology.
[6] H. Dvorak,et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.
[7] H. Dvorak,et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. , 1995, The Journal of investigative dermatology.
[8] R. Warren,et al. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. , 1995, The Journal of clinical investigation.
[9] E. Manseau,et al. Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. , 1995, Journal of Immunology.
[10] Kenneth M. Yamada,et al. Synergistic roles for receptor occupancy and aggregation in integrin transmembrane function , 1995, Science.
[11] Z. Khalkhali‐Ellis,et al. Enhanced expression of alpha v integrin subunit and osteopontin during differentiation of HL-60 cells along the monocytic pathway. , 1995, Experimental cell research.
[12] R. Ross,et al. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. , 1995, The Journal of clinical investigation.
[13] Lois E. H. Smith,et al. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[14] D. Cheresh,et al. Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.
[15] L. Aiello,et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.
[16] S M Schwartz,et al. Macrophages express osteopontin during repair of myocardial necrosis. , 1994, The American journal of pathology.
[17] R. Klemke,et al. Receptor tyrosine kinase signaling required for integrin alpha v beta 5- directed cell motility but not adhesion on vitronectin , 1994, The Journal of cell biology.
[18] E. Manseau,et al. Osteopontin expression and distribution in human carcinomas. , 1994, The American journal of pathology.
[19] E. Brown,et al. Basic Fibroblast Growth Factor Increases Expression of the αvβ3 Integrin Complex on Human Microvascular Endothelial Cells , 1994 .
[20] H. Dvorak,et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis , 1994, The Journal of experimental medicine.
[21] J. Moringlane,et al. Detection and quantification of vascular endothelial growth factor/vascular permeability factor in brain tumor tissue and cyst fluid: the key to angiogenesis? , 1994, Neurosurgery.
[22] E. Keshet,et al. Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. , 1994, Cardiovascular research.
[23] N. Olsen,et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue , 1994, The Journal of experimental medicine.
[24] Timothy A. Springer,et al. The dynamic regulation of integrin adhesiveness , 1994, Current Biology.
[25] L. Water,et al. Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. , 1994, Molecular biology of the cell.
[26] D. Cheresh,et al. Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.
[27] M. Schwartz,et al. Alpha v integrins mediate the rise in intracellular calcium in endothelial cells on fibronectin even though they play a minor role in adhesion. , 1994 .
[28] A. Mukherjee,et al. Osteopontin: its transglutaminase-catalyzed posttranslational modifications and cross-linking to fibronectin. , 1994, Journal of biochemistry.
[29] D. G. Chalupowicz,et al. Transglutaminase-mediated processing of fibronectin by endothelial cell monolayers. , 1994, Biochemistry.
[30] S. Schwartz,et al. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. , 1994, Circulation research.
[31] E. Brogi,et al. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. , 1994, The Journal of clinical investigation.
[32] D. Denhardt,et al. Osteopontin: a protein with diverse functions , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[33] E. Manseau,et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. , 1993, The American journal of pathology.
[34] E. Bendixen,et al. Transglutaminases catalyze cross-linking of plasminogen to fibronectin and human endothelial cells. , 1993, The Journal of biological chemistry.
[35] L. Williams,et al. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[36] E. Manseau,et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. , 1993, Cancer research.
[37] D. Rifkin,et al. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. , 1993, Molecular biology of the cell.
[38] T. Quinn,et al. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[39] M. Bourdon,et al. Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. , 1993, Journal of cell science.
[40] H. Dvorak,et al. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. , 1993, Cancer research.
[41] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[42] E. Oldfield,et al. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues. , 1993, The American journal of physiology.
[43] A. Ullrich,et al. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis , 1993, Cell.
[44] H. Dvorak,et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing , 1992, The Journal of experimental medicine.
[45] E. Keshet,et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.
[46] D. Dimitrov,et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. , 1992, Biochemical and biophysical research communications.
[47] B. Spiegelman,et al. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways. , 1992, The Journal of biological chemistry.
[48] D. Leavesley,et al. Requirement of the integrin beta 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen , 1992, The Journal of cell biology.
[49] Richard O. Hynes,et al. Integrins: Versatility, modulation, and signaling in cell adhesion , 1992, Cell.
[50] H Ueno,et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. , 1992, Science.
[51] George E. Davis,et al. Affinity of integrins for damaged extracellular matrix: αvβ3 binds to denatured collagen type I through RGD sites , 1992 .
[52] N. Ferrara,et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. , 1992, Endocrine reviews.
[53] L. Orci,et al. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. , 1991, Biochemical and biophysical research communications.
[54] C. W. Prince,et al. Osteopontin, a substrate for transglutaminase and factor XIII activity. , 1991, Biochemical and biophysical research communications.
[55] M. Detmar,et al. Effects of recombinant tumor necrosis factor-alpha on cultured microvascular endothelial cells derived from human dermis. , 1990, The Journal of investigative dermatology.
[56] C. Semenkovich,et al. A protein partially expressed on the surface of HepG2 cells that binds lipoproteins specifically is nucleolin. , 1990, Biochemistry.
[57] W. T. Chen,et al. Monoclonal antibody and synthetic peptide inhibitors of human tumor cell migration. , 1990, Cancer research.
[58] D. Connolly,et al. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. , 1990, Cancer research.
[59] D. Connolly,et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. , 1989, The Journal of clinical investigation.
[60] D. Gospodarowicz,et al. Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[61] C. Perruzzi,et al. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. , 1989, Anticancer research.
[62] W. T. Chen,et al. Analysis of fibronectin receptor function with monoclonal antibodies: roles in cell adhesion, migration, matrix assembly, and cytoskeletal organization , 1989, The Journal of cell biology.
[63] N. Ferrara,et al. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.
[64] D. Tenen,et al. Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. , 1989, Biochimica et biophysica acta.
[65] P. Barr,et al. The cDNA and derived amino acid sequence for human osteopontin. , 1989, Nucleic acids research.
[66] D. Tenen,et al. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. , 1988, Cancer research.
[67] D. Cheresh,et al. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor. , 1987, The Journal of biological chemistry.
[68] M. Poncz,et al. Comparison of cDNA-derived protein sequences of the human fibronectin and vitronectin receptor alpha-subunits and platelet glycoprotein IIb. , 1987, Biochemistry.
[69] S. Lo,et al. Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to "integrin". , 1987, The Journal of biological chemistry.
[70] H. Dvorak,et al. Regulation of extravascular coagulation by microvascular permeability. , 1985, Science.
[71] H. Dvorak,et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.
[72] U. K. Laemmli,et al. Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.
[73] E. Manseau,et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. , 1996, Cancer research.
[74] D. Ruiter,et al. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. , 1995, The American journal of pathology.
[75] D. Cheresh,et al. An antagonist of integrin αvβ3 prevents maturation of blood vessels during embryonic neovascularization , 1995 .
[76] R. Klemke,et al. Receptor Tyrosine Kinase Signaling Required for Integrin c v/35-directed Cell Motility but Not Adhesion on Vitronectin , 1994 .
[77] J. Folkman,et al. Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes With Proliferative Diabetic Retinopathy , 1995 .
[78] W. Reinhold,et al. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. , 1993, The Journal of clinical investigation.
[79] M. Bourdon,et al. Endothelial cell attachment and spreading on human tenascin is mediated by 2 1 and V 3 integrins , 2022 .